Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer

• Publication date

  2004-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/cncr.20709PMID 15536623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toxic proteins released from mitochondria in cell death

  2004influential reference
• Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells

  2004cited by this paper
• Class II histone deacetylases: versatile regulators.

  2003cited by this paper
• Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells.

  2003cited by this paper
• Histone deacetylases (HDACs): characterization of the classical HDAC family.

  2003cited by this paper
• Sodium butyrate induces growth arrest and senescence‐like phenotypes in gynecologic cancer cells

  2001influential reference
• Rapid Induction of Histone Hyperacetylation and Cellular Differentiation in Human Breast Tumor Cell Lines following Degradation of Histone Deacetylase-1*

  2000cited by this paper
• The language of covalent histone modifications

  2000cited by this paper
• Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

  2000cited by this paper
• Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

  2000cited by this paper
• Cyclins and cell cycle checkpoints.

  1999cited by this paper
• Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO

  1998cited by this paper
• The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.

  1998cited by this paper
• Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

  1998cited by this paper
• Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression.

  1997cited by this paper
• Direct inhibition of the expression of cyclin D1 gene by sodium butyrate.

  1996cited by this paper
• Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities

  1995cited by this paper
• Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function

  1995cited by this paper
• E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.

  1995cited by this paper
• Cadherin cell adhesion receptors as a morphogenetic regulator.

  1991cited by this paper
• Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.

  1990cited by this paper
• Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells.

  1990cited by this paper
• Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1

  1988cited by this paper
• Mechanism of anticonvulsant action of valproate

  1982influential reference

• Valproate Mediated Proteasome Dysfunctions Induce Apoptosis

  2024cites this paper
• Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils

  2024cites this paper
• Effect of vorinostat on protein expression in vitro and in vivo following mRNA lipoplex administration

  2024cites this paper
• Vorinostat (SAHA) and Breast Cancer: An Overview

  2021cites this paper
• A valproic acid-modified platinum diimine complex as potential photosensitizer for photodynamic therapy.

  2021cites this paper
• Bipolar Disorder Treatments and Ovarian Cancer: A Systematic Review

  2020cites this paper
• Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes

  2020cites this paper
• Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

  2019cites this paper
• The effect of sodium butyrate and cisplatin on expression of EMT markers

  2019cites this paper
• Epigenomics of Ovarian Cancer and Its Chemoprevention

  2019cites this paper
• Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells

  2019cites this paper
• Zebularine significantly improves the preimplantation development of ovine somatic cell nuclear transfer embryos.

  2019cites this paper
• Profound Inhibitory and Apoptotic Effects of Histone Deacetylase Inhibitor Valproic Acid on Different Cancers

  2019cites this paper
• Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells

  2018influential citation
• Trichostatin A activates FOXO1 and induces autophagy in osteosarcoma

  2018cites this paper
• Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands

  2018cites this paper
• EFFECT OF VALPROIC ACID IN COMPARISON WITH VORINOSTAT ON CELL GROWTH INHIBITION AND APOPTOSIS INDUCTION IN THE HUMAN COLON CANCER SW 48 CELLS IN VITRO

  2018cites this paper
• Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.

  2018cites this paper
• Molecular mechanisms underlying the action of histone deacetylases inhibitors (HDACIs) in ovarian cancer

  2017cites this paper
• A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth

  2017cites this paper
• In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells

  2017cites this paper
• Valproic Acid-Functionalized Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.

  2017cites this paper
• Chapter 3 – Epigenetics

  2017cites this paper
• Non-Coding RNAs in Ovarian Cancer

  2017cites this paper
• HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells

  2017cites this paper
• SiRNA and epigenetic aberrations in ovarian cancer.

  2016cites this paper
• histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2–p53 signaling

  2016cites this paper
• Valproic Acid as a Promising Co-Treatment With Paclitaxel and Doxorubicin in Different Ovarian Carcinoma Cell Lines

  2016cites this paper
• Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2–p53 signaling

  2016cites this paper
• Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases

  2016cites this paper
• Ovarian cancer and the immune system - The role of targeted therapies.

  2016cites this paper
• Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies.

  2016cites this paper
• Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.

  2016cites this paper
• The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer

  2016cites this paper
• Epigenetic inhibitors.

  2015cites this paper
• Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer

  2015cites this paper
• Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

  2015cites this paper
• Cancer Epigenetics

  2015cites this paper
• Effects of Scriptaid on Cell Cycle and Histone Acetylation of Ovine Nuclear Donor Cumulus Cells and their Ability to Support the Development of Somatic Cell Nuclear Transfer Embryos

  2015cites this paper
• Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer

  2015cites this paper
• Endometrial Cancer Stem Cell as a Potential Therapeutic Target

  2015cites this paper
• Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets

  2014cites this paper
• Canonical and new generation anticancer drugs also target energy metabolism

  2014cites this paper
• Valproic acid suppresses growth and enhances cisplatin cytotoxicity to larynx cancer cells

  2014cites this paper
• Characterization of novel epigenetic targets in ovarian cancer

  2014cites this paper
• Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms

  2014cites this paper
• Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.

  2014cites this paper
• Aberrant histone modification in endometriosis.

  2014cites this paper
• Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.

  2013cites this paper
• Molecular Mechanisms of Hereditary Diffuse Gastric Cancer Initiation and Progression

  2013cites this paper
• Effects of LBH589 alone or in combination with DTX on the proliferation and apoptosis of the human ovarian cancer line OVCAR-3

  2013cites this paper
• Multiparameter flow cytometric immunophenotyping of epithelial cells in effusions. Technical improvements and apoptosis measurement.

  2013cites this paper
• Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.

  2013cites this paper
• Lipopolysaccharide prevents valproic acid-induced apoptosis via activation of nuclear factor-κB and inhibition of p53 activation.

  2013cites this paper
• Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery

  2013cites this paper
• Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells

  2013influential citation
• Comparison of the effects of valproic acid and levetiracetam on apoptosis in the human ovarian cancer cell line OVCAR-3

  2012cites this paper
• SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin

  2012cites this paper
• Effects of valproic acid and levetiracetam on viability and cell cycle regulatory genes expression in the OVCAR-3 cell line

  2012influential citation
• Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.

  2012cites this paper
• Valproic acid: Growth inhibition of head and neck cancer by induction of terminal differentiation and senescence

  2012cites this paper
• Endometrial cancer stem cells: a new target for cancer therapy.

  2012cites this paper
• Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy.

  2012cites this paper
• Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice.

  2012cites this paper
• Comparison of the effects of valproic acid and levetiracetam on apoptosis in the human ovarian cancer cell line OVCAR-3

  2012cites this paper
• Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.

  2011influential citation
• Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.

  2011cites this paper
• Preclinical Development Sodium Butyrate Inhibits the Self-Renewal Capacity of Endometrial Tumor Side-Population Cells by Inducing a DNA Damage Response

  2011cites this paper
• Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression.

  2011cites this paper
• The effect of valproic acid on histone acetylation in FaDu-luc head and neck squamous cell carcinoma cells

  2011cites this paper
• Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.

  2011cites this paper
• The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines

  2011cites this paper
• Valproic acid induces microglial dysfunction, not apoptosis, in human glial cultures.

  2011cites this paper
• Sodium Butyrate Inhibits the Self-Renewal Capacity of Endometrial Tumor Side-Population Cells by Inducing a DNA Damage Response

  2011cites this paper
• Cell cycle and energy metabolism in tumor cells: strategies for drug therapy.

  2011cites this paper
• Controversies in the Management of Endometrial Cancer

  2010cites this paper
• The emerging role of lysine acetylation of non-nuclear proteins

  2010cites this paper
• Histone deacetylase inhibitor enhances sensitivity of non‐small‐cell lung cancer cells to 5‐FU/S‐1 via down‐regulation of thymidylate synthase expression and up‐regulation of p21waf1/cip1 expression

  2010cites this paper
• Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin

  2010cites this paper
• Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer

  2010cites this paper
• Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells

  2010cites this paper
• Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients.

  2010cites this paper
• Epigenetic Therapy in Human Choriocarcinoma

  2010cites this paper
• Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.

  2010cites this paper
• The control of adult neural stem cell proliferation and cognition by valproic acid

  2010cites this paper
• The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer

  2010cites this paper
• Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

  2010cites this paper
• Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas.

  2009cites this paper
• A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

  2009cites this paper
• Epigenetics and ovarian cancer.

  2009cites this paper
• Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors

  2009cites this paper
• Antitumour activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo

  2009cites this paper
• Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer

  2009cites this paper
• Notch 1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors

  2009cites this paper
• Glucose metabolism as a target of histone deacetylase inhibitors.

  2009cites this paper
• Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.

  2009cites this paper
• Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells.

  2008cites this paper
• A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

  2008cites this paper
• Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells.

  2008cites this paper
• Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.

  2008cites this paper